Market Place
Sourcing Support
Lexeo Therapeutics Joins Leerink Global Healthcare Conference
03 Mar 2026 //
GLOBENEWSWIRE
Lexeo links gene therapy to improvements in rare heart disease
16 Jul 2024 //
BIOSPACE
Lexeo To Report LX2006 Interim Data For Friedreich Ataxia Cardiomyopathy
11 Jul 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
08 Jul 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Q1 2024 Financials And Highlights
09 May 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
07 May 2024 //
GLOBENEWSWIRE
Lexeo Announces Closing of Oversubscribed $95.0 Million Equity Financing
13 Mar 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11 Mar 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
Lexeo Strengthens Clinical Development Leadership with Executive Appointments
05 Feb 2024 //
GLOBENEWSWIRE
Lexeo to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results
11 Dec 2023 //
GLOBENEWSWIRE
Lexeo drops share price at last minute to raise $100M IPO
03 Nov 2023 //
FIERCE BIOTECH
Lexeo Therapeutics Announces Pricing of Initial Public Offering
02 Nov 2023 //
GLOBENEWSWIRE
LEXEO Therapeutics Announces FDA Clearance of IND for LX2020
01 Aug 2023 //
GLOBENEWSWIRE
LEXEO Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment
02 Nov 2022 //
BIOSPACE
LEXEO Therapeutics to Present Clinical and Preclinical Data at Conferences
27 Oct 2022 //
GLOBENEWSWIRE
LEXEO Receives Orphan Drug Designation for LX1004 from European Commission
18 Oct 2022 //
GLOBENEWSWIRE
LEXEO to Present New Clinical Data from its Investigational Gene Therapy LX1001
05 Oct 2022 //
GLOBENEWSWIRE
LEXEO Therapeutics Announces Data Presentations at the 25th ASGCT
03 May 2022 //
GLOBENEWSWIRE
LEXEO Therapeutics to Participate in Upcoming Investor Conferences
21 Mar 2022 //
GLOBENEWSWIRE
LEXEO Tx Announces Positive Initial Data from Ongoing Phase 1/2 Trial of LX1001
02 Mar 2022 //
GLOBENEWSWIRE
FDA Clears LEXEO`s IND for LX2006 in Friedreich’s Ataxia Cardiomyopathy
16 Feb 2022 //
GLOBENEWSWIRE
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration
13 Oct 2021 //
GLOBENEWSWIRE
Lexeo Therapeutics and FUJIFILM announce partnership gene therapies
13 Oct 2021 //
PHARMAFILE
Retrotope misses mark but boosts survival in rare child disorder
07 Oct 2021 //
FIERCEBIOTECH
LEXEO Pediatric Disease Designation Orphan Drug Designation for LX1004
28 Jul 2021 //
GLOBENEWSWIRE
LEXEO Gene Therapy Acquisition Stelios Gene Therapy Rare Cardiovascular Diseases
21 Jul 2021 //
GLOBENEWSWIRE
Lexeo bolsters rare heart disease pipeline with Stelios buy
21 Jul 2021 //
FIERCEBIOTECH
LEXEO Therapeutics Announces Upcoming Data Presentations at the (ASGCT) 2021
28 Apr 2021 //
GLOBENEWSWIRE
LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001
20 Apr 2021 //
GLOBENEWSWIRE
LEXEO Announces License Agreement and Consolidation of Pre-clinical Data
01 Mar 2021 //
GLOBENEWSWIRE
